Note 11. Subsequent Event

In July 2026, the Company formed Open Medicine AI Inc. (“Open Medicine AI”) as a wholly-owned subsidiary to commercialize and expand the multi-agent AI co-scientist platform originally launched as withZeta.ai. In connection with the formation of Open Medicine AI, the Company entered into asset contribution and license agreements granting Open Medicine AI access to Lantern’s withZeta.ai-related models, data, algorithms, and other assets. The Open-Medicine AI multi-agentic co-scientist platform represents the strategic evolution of withZeta.ai, including the planned expansion into additional disease areas and modalities.

In exchange for the contribution of the withZeta.ai assets to Open Medicine AI, Lantern received 5,000,000 shares of Open Medicine AI common stock. Lantern also entered into a License Agreement with Open Medicine AI providing access to the withZeta.ai-related models, data, and algorithms. The formation of Open Medicine AI and the contribution of the withZeta.ai assets to Open Medicine AI are consistent with the framework outlined as part of the Company’s May 2026 Offering.